Publications by authors named "E M Fontana"
Fewer than 50% of metastatic deficient mismatch repair (dMMR) colorectal cancer (CRC) patients respond to immune checkpoint inhibition (ICI). Identifying and expanding this patient population remains a pressing clinical need. Here, we report that an interferon-high immunophenotype locally enriched in cytotoxic lymphocytes and antigen-presenting macrophages is required for response.
View Article and Find Full Text PDFBackground: High expression of programmed death-ligand 1 (PD-L1) has been recognized as a marker of improved efficacy of immunotherapy in gastroesophageal adenocarcinoma (GEA); however, the optimal PD-L1 cut-off is still debated. The aim of the present review was to analyze available phase III trials and to identify the appropriate PD-L1 expression cut-off for GEA.
Methods: Phase III trials investigating the efficacy of anti-programmed cell death protein 1 (PD-1) therapies in addition to standard chemotherapy versus standard chemotherapy in the first-line setting were selected.
Article Synopsis
- * In research using a mouse model that mimics ARO, gene therapy (GT) with lentiviral vectors effectively improved bone density and allowed for long-term survival, while also enhancing the collection of necessary stem cells through a method called plerixafor-induced mobilization.
- * The study suggests that non-genotoxic conditioning before transplantation can lead to better outcomes, including stable stem cell engraftment and improved bone health, providing a
Article Synopsis
- The article you're looking at has a special code called a DOI that helps find it online.
- This specific DOI (10.3389/fimmu.2011.00015) is linked to a research paper about immune science.
- The text mentions that there was a correction made to that original article.
Purpose: BT5528 is a Bicycle Toxin Conjugate, a novel class of chemically synthesized molecules, comprising a bicyclic peptide targeting EphA2 tumor antigen, linked to a cytotoxin (monomethyl auristatin E [MMAE]). EphA2 is overexpressed in many solid tumors and contributes to oncogenesis, tumor-associated angiogenesis, and metastasis.
Materials And Methods: The primary objectives were to investigate the safety and tolerability of BT5528 and to define the maximum-tolerated dose, if observed, and recommended phase II dose (RP2D)/expansion dose.